- Home
- KIRK vs CVKD Comparison
KIRK vs CVKD Comparison
Compare KIRK & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIRK
- CVKD
- Stock Information
- Founded
- KIRK 1966
- CVKD 2022
- Country
- KIRK United States
- CVKD United States
- Employees
- KIRK N/A
- CVKD N/A
- Industry
- KIRK Diversified Commercial Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- KIRK Miscellaneous
- CVKD Health Care
- Exchange
- KIRK Nasdaq
- CVKD Nasdaq
- Market Cap
- KIRK 26.7M
- CVKD 29.5M
- IPO Year
- KIRK 2002
- CVKD 2023
- Fundamental
- Price
- KIRK $1.20
- CVKD $11.37
- Analyst Decision
- KIRK Buy
- CVKD Strong Buy
- Analyst Count
- KIRK 2
- CVKD 1
- Target Price
- KIRK $4.50
- CVKD $32.00
- AVG Volume (30 Days)
- KIRK 137.6K
- CVKD 36.4K
- Earning Date
- KIRK 09-04-2025
- CVKD 08-06-2025
- Dividend Yield
- KIRK N/A
- CVKD N/A
- EPS Growth
- KIRK N/A
- CVKD N/A
- EPS
- KIRK N/A
- CVKD N/A
- Revenue
- KIRK $431,111,000.00
- CVKD N/A
- Revenue This Year
- KIRK N/A
- CVKD N/A
- Revenue Next Year
- KIRK N/A
- CVKD N/A
- P/E Ratio
- KIRK N/A
- CVKD N/A
- Revenue Growth
- KIRK N/A
- CVKD N/A
- 52 Week Low
- KIRK $1.05
- CVKD $5.70
- 52 Week High
- KIRK $2.50
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- KIRK 56.91
- CVKD 39.88
- Support Level
- KIRK $1.13
- CVKD $11.15
- Resistance Level
- KIRK $1.22
- CVKD $12.26
- Average True Range (ATR)
- KIRK 0.04
- CVKD 1.07
- MACD
- KIRK 0.01
- CVKD 0.01
- Stochastic Oscillator
- KIRK 93.06
- CVKD 13.68
About KIRK Kirkland's Inc. COMMONSTOCK
Kirkland's Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.